ADXN Addex Therapeutics Ltd Forecast, Technical & Fundamental Analysis

ADXN sees its Stochastic Oscillator recovers from oversold territory

On January 31, 2025, the Stochastic Oscillator for ADXN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 72 instances where the indicator left the oversold zone. In of the 72 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 04, 2025. You may want to consider a long position or call options on ADXN as a result. In of 122 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ADXN just turned positive on February 04, 2025. Looking at past instances where ADXN's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADXN advanced for three days, in of 193 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

ADXN moved below its 50-day moving average on February 05, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADXN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ADXN entered a downward trend on February 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.657) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.012). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.602). ADXN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (9.699) is also within normal values, averaging (250.738).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ADXN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADXN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.